Heart in Diabetes 9th Annual Heart in Diabetes Conference 2025

• Target Audience: cardiologists, endocrinologists, and nephrologists
• Sample video: contact me for sample video
• Information:

1. Overview

Course Date: 2025

2. Learning Objectives

Evaluate the pathophysiology and clinical management of cardiorenal metabolic diseases, including resistant hypertension and diabetic cardiomyopathy.

Implement guideline-directed medical therapies using GLP-1 RAs, SGLT2 inhibitors, and novel MRAs to optimize cardio-renal protection in patients with diabetes.

Analyze the systemic impact of sleep disorders, hypercortisolism, and women-specific risk factors on cardiovascular and metabolic health.

Assess the latest cardiovascular outcome trials (CVOTs) and integrate emerging lipid-lowering treatments targeting ApoB and CETP into clinical practice.

Apply digital health technologies, intensive lifestyle interventions, and multidisciplinary approaches to manage complex cases involving obesity and heart failure.

3. Target Audience

Best for cardiologists, endocrinologists, and nephrologists who want updates on cardiorenal metabolic therapies, clinical trials, and obesity.

4. Topics

Day 1 01 Epidemiology and Pathophysiology of Resistant Hypertension and CKD Treatment

Day 1 02 Management of Chronic Kidney Disease With or Without Albuminuria

Day 1 03 Emerging Approaches to the Treatment of Resistant Hypertension

Day 1 04 Case Presentation – Treatment Resistant Hypertension

Day 1 05 Cortisol – Impact on Endocrinology & Metabolism

Day 1 06 Cortisol’s Impact on the Kidney-BP-Bone

Day 1 07 Cardiovascular Implications of Hypercortisolism

Day 1 08 Panel Discussion and Q&A – Cortisol & Cardiorenalmetabolic Diseases

Day 1 09 MASLD and MASH – Pathophysiology, Diagnosis and Management

Day 1 10 Sleep Health – Implications for Obesity and Diabetes Risk

Day 1 11 Sleep and Cardiovascular Risk

Day 1 12 Panel Discussion and Q&A – Sleep Disorders in Cardiometabolism

Day 1 13 Prediabetes – What’s a Clinician to Do

Day 1 14 Unraveling the Connection – Diabetes and Dementia

Day 1 15 Pulmonary Disorders in Diabetes – Implications for Heart Disease

Day 1 16 Diabetes and Cardiovascular Disease in Older Adults

Day 1 17 Panel Discussion and Q&A – Diabetes Comorbidities

Day 1 18 Implementing Guideline-Directed Medical Therapy – Stakeholder-Identified Barriers and Facilitators

Day 1 19 Population Health Approaches to Accelerate the Prevention of CVD – Moving from Action to Impact

Day 1 20 Panel Discussion and Q&A – Implementation Science in Practice

Day 1 21 Dyslipidemia in Women Across a Lifetime Approach to Management

Day 1 22 Sex Hormones and Anthropometric Measures & Heart Failure Risk in Women

Day 1 23 Panel Discussion and Q&A – Women’s Health

Day 1 25 Optimal Strategy for Heart Failure Screening Among Adults With Diabetes Without ASCVD – A Pooled Cohort Analysis

Day 1 26 Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibro…

Day 1 27 Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Chronic Kidney Disease

Day 1 28 Panel Discussion and Q&A – Circulation

Day 2 01 Current Trends in Epidemiology of Heart Failure – USA

Day 2 02 Diabetic Cardiomyopathy – Mechanisms and Future Directions

Day 2 03 Bromocriptine in the Treatment of Peripartum Cardiomyopathy – Is It Ready for Prime Time

Day 2 04 Proper Medical Management of HFpEF in 2025

Day 2 05 Panel Discussion and Q&A – Heart Failure – The Now & The New

Day 2 06 GLP1-RA, Obesity & Diabetes – Mechanisms of Cardiovascular Protection

Day 2 07 Cardio-Kidney Protection With Incretin Therapies

Day 2 08 Incretins – Today and Tomorrow

Day 2 09 Panel Discussion and Q&A – Current & Future Role of Incretin Therapy

Day 2 10 Diabetes and Cardiovascular Disease – The Evolution of CV Outcomes Assessment of Antihyperglycemic Medications

Day 2 11 My Personal Journey to HoFH Diagnosis

Day 2 12 From Rare to the Very Common – Role of Genetics in Lipid Disorders

Day 2 13 CETPi – Where Might They Fit Into Clinical Practice

Day 2 14 Using ApoB in Clinical Practice – From Risk Assessment to Treatment Targets

Day 2 15 Obesity and Dyslipidemia – Can We Finally Break the Cycle With Dual Agonists

Day 2 16 The Epidemiology and Pathophysiology of Cardio-Kidney-Metabolic Diseases

Day 2 17 Unmet Needs in CKD in T1D and Challenges in CKD Beyond Diabetes

Day 2 18 Finerenone Across the Stages of Heart Failure – From Prevention to Treatment

Day 2 19 Panel Discussion and Q&A – Cardio-Renal Protection in CKM Diseases

Day 2 20 Digital Health Technologies for Cardiometabolic Disease & Diabetes

Day 2 22 Intensive Lifestyle Intervention, Cardiac Biomarkers, and Cardiovascular Outcomes in Diabetes – The Look AHEAD Cardiac…

Day 2 24 Panel Discussion and Q&A – JACC

Day 2 25 Technology in the Management of Diabetes – Addressing Its Role in Comorbidities

Day 2 26 SGLT2 Inhibitors – Reconsidering, Repurposing, Reimagining

Day 2 27 Panel Discussion and Q&A – Diabetes Management & Technology

Day 3 01 Management of Complex Cases – Obesity and Heart Failure

Day 3 02 The Edema Dilemma – A Case of Diabetes Mellitus, Heart Failure With Preserved Ejection Fraction, Obesity, Chronic Kidne…

Day 3 03 CRM Management of Complex Cases

Day 3 04 The Lancet Commission on Obesity

Day 3 05 Obesity – Role of Medical Management

Day 3 06 Management of Obesity Addressing Lean Mass Preservation

Day 3 07 Panel Discussion and Q&A – Obesity

Day 3 08 Do ACEiARB Still Have a Role in the Era of SGLT2, MRA and GLP1A

Day 3 09 The Role of Diastolic & Pulse Pressure in CKD & CVD – Management Considerations

Day 3 10 Aldosterone – The Forgotten Hormone in Hypertension

Day 3 11 Panel Discussion and Q&A – The Kidney and Hypertension

Day 3 12 Combination Treatment to Improve Heart and Kidney Outcomes in Diabetic Kidney Disease

Day 3 13 The Latest Heart Disease & Stroke Statistics – US & Global Data from the American Heart Association

Day 3 14 Appropriate Cardiac Intervention in the Diabetes Cardiorenal & Metabolic Medicine Patient

Day 3 15 Serum Lipoproteins & Coronary Atherosclerosis in Asymptomatic U.S. Adults Without Traditional Risk Factors

Day 3 16 Cardiovascular Outcome Trials Update

Day 3 17 Panel Discussion and Q&A – ASCVD